Answers are grounded in this paper and cite their sources.
Oxaliplatin, a platinum-based compound, is the standard cancer therapy for treatment of metastatic colorectal carcinoma and other gastrointestinal malignancies. Oxaliplatin-induced nephrotoxicities include acute kidney injury due to acute tubular injury secondary to diarrhea and pre-renal azotemia, though intravascular hemolysis and thrombotic microangiopathy have been also reported. Patients with oxaliplatin-induced kidney failure partially recover kidney function after cessation of oxaliplatin therapy. We report a unique case of a 61-year-old female, with metastatic colon cancer to her lungs, liver, spleen, and peritoneum, who presented with acute anemia, sepsis, and kidney failure post-oxaliplatin treatment. Oxaliplatin cessation resulted in complete kidney recovery after 3 months of kidney replacement therapy.
No takes yet. Share an insight, caveat, or question.
Hanna et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: